37. The method of claim 16 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

38. The method of claim 16 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α-linolenic acid, EPA, DPA and DHA.

39. The method of claim 16 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ-linolenic acid (18:3, n-6), dihomo-γ-linoleninic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

40. The method of claim 16 wherein the composition is administered enterally.

REMARKS

Pursuant to this Preliminary Amendment, Claims 1-8 have been amended and newly-submitted Claims 9-40 have been added. Additionally, minor amendments have been made to the specification.

The Preliminary Amendment does not add new matter. Moreover, Applicants note for the record, the Preliminary Amendment is not being used for purposes of narrowing the claims to avoid prior art. Rather, the Preliminary Amendment is being made to place the claims in proper U.S. format as well as add additional claims. Therefore, Applicants do not intend to disclaim any subject matter in view of this Preliminary Amendment.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Versions with Markings to Show Changes Made.**"

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY _____

Robert M. Barrett
Reg. No. 30,142
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (312) 807-4204

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

On page 1, line 1, delete "High Lipid Diet" and substitute the following:

--SPECIFICATION

TITLE OF THE INVENTION

"HIGH LIPID DIET"--

On page 1, at line 37, insert the following:

--SUMMARY OF THE INVENTION--

On page 6, line 22, please delete "specific embodiments of the invention will now be described in detail with reference to the accompanying drawings in which" and substitute therefor --Additional features and advantages of the present invention are described in and will be apparent from the Detailed Description of the Presently Preferred Embodiments and the drawings.

BRIEF DESCRIPTION OF THE DRAWINGS--

On page 7, line 13, please insert:

--DETAILED DESCRIPTION OF THE INVENTION

The present invention provides improved compositions as well as methods of treatment. More specifically, the composition of the present invention and treatment can be used for the treatment or prevention of sepsis or inflammatory shock.

By way of example and not limitation, examples of the present invention will now be set forth.--

In the Claims:

Please amend Claims 1-8 as follows:

1. (Amended) [Use] A method of treating sepsis comprising the steps of administering to a patient with sepsis a therapeutically effective amount of a composition[,] which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy

of the composition [for use in the manufacture of a medicament, functional food or nutritive product for the treatment or prevention of sepsis or inflammatory shock].

2. (Amended) A method of [treatment or prevention of] reducing the risk of sepsis ~~[or inflammatory shock which]~~ comprising the steps of administering to a patient at risk of sepsis comprises [administering an] a therapeutically effective amount of a composition, which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition.

3. (Amended) A method of producing a composition which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition, [having] comprising the steps of blending [the] constituents including at least one lipid, liquefying [the] a blended mixture and homogenising the liquefied blended mixture to produce a product wherein greater than 35% of the total energy of the composition is provided by lipid.

4. (Amended) A composition [for use as a medicament, functional food or nutritive product, which comprises] comprising at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition, [which further comprises] about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

5. (Amended) A composition according to claim 4, which comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

6. (Amended) A composition according to claim 4 [or 5], which comprises at least one n-3 fatty acid selected from the group consisting of α-linolenic acid, EPA, DPA [or] and DHA.

7. (Amended) A composition according to [any of] claim 4 [to 6], which comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ-linolenic acid (18:3, n-6), dihomo-γ-linoleninic acid (18:4, n-6) [or] and arachidonic acid (20:4, n-6).

8. (Amended) A composition according to [any of] claim 4 [to 7] for enteral administration which [comprises] includes at least one component selected from the group consisting of an acceptable carrier, diluent [or] and adjuvant.

Please add newly-submitted Claims 9-40 as follows:

9. The method of claim 1 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

10. A method of treating inflammatory shock comprising the step of administering to a patient suffering inflammatory shock a therapeutically effective amount of a composition which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition.

11. The method of claim 1 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

12. The method of claim 1 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

13. The method of claim 1 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α-linolenic acid, EPA, DPA and DHA.

14. The method of claim 1 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ-linolenic acid (18:3, n-6), dihomo-γ-linoleninic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

15. The method of claim 1 wherein the composition is administered enterally.

16. A method for reducing the risk of inflammatory shock comprising the step of administering to a patient at risk of inflammatory shock a therapeutically effective amount of a composition which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition.

17. The method of claim 2 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

18. The method of claim 2 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

19. The method of claim 2 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

20. The method of claim 2 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α-linolenic acid, EPA, DPA and DHA.

21. The method of claim 2 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ-linolenic acid (18:3, n-6), dihomo-γ-linoleninic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

22. The method of claim 2 wherein the composition is administered enterally.

23. The method of claim 3 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

24. The method of claim 3 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

25. The method of claim 3 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

26. The method of claim 3 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α-linolenic acid, EPA, DPA and DHA.

27. The method of claim 3 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ-linolenic acid (18:3, n-6), dihomo-γ-linoleninic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

28. The method of claim 3 wherein the composition is administered enterally.

29. The method of claim 10 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

30. The method of claim 10 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

31. The method of claim 10 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

32. The method of claim 10 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α-linolenic acid, EPA, DPA and DHA.

33. The method of claim 10 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ-linolenic acid (18:3, n-6), dihomo-γ-linoleninic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

34. The method of claim 10 wherein the composition is administered enterally.

35. The method of claim 16 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

36. The method of claim 16 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

37. The method of claim 16 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

38. The method of claim 16 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α-linolenic acid, EPA, DPA and DHA.

39. The method of claim 16 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ-linolenic acid (18:3, n-6), dihomo-γ-linoleninic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

40. The method of claim 16 wherein the composition is administered enterally.